Abstract: Pyoderma gangrenosum is a rare neutrophilic dermatosis, which usually presents as ulcers with erythematous-violaceous undermined edges and a rough base with purulent or sanguinous exudate. It can be primary or associated with an underlying disease. However, rare cases of its association with autoimmune hepatitis have been described in the literature. Diagnosis is based on a characteristic clinical picture and ruling out other causes of ulcers. This paper aims to discuss the management of corticosteroid therapy and the importance of local treatment. We report a case with torpid evolution, presented with multiple and deep ulcers in a young patient with autoimmune hepatitis, causing pain and significant disability. We observed complete healing of lesions after two months of successful treatment.
INTRODUCTION
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis, with an estimated annual incidence of 3-10 cases per million in the population. 1 It can present itself as a primary disorder or be associated with an underlying disease, particularly inflammatory bowel disease (IBD), arthritis, hematologic diseases, and malignant diseases. 2 Typical clinical presentation consists of a pustule or nodule that evolves into a painful ulcer with an undermined and well-defined erythematous-violaceous border. The base of the ulcer commonly has granulation tissue with purulent or sanguinous exudate.
It is usually located on lower limbs and displays centrifugal growth.
Other possible forms of presentation include vegetative, bullous, and pustular types.
Its frequent association with autoimmune diseases and pathergy corroborate the hypothesis of PG as an autoimmune disease. 3 Pathergy, which occurs in about 30% of cases, consists of the appearance of new lesions or the worsening of pre-existing lesions after a local trauma. 4 The diagnosis is made -in addition to its compatible clinical characteristics -by excluding other causes of similar-appearing cutaneous ulcerations -including infection, malignancy, and vasculitis -by histopathological examination and laboratory study.
The treatment of secondary PG should consider the treatment of the underlying disease. In primary PG, corticosteroid therapy is the gold standard, sometimes in combination with immunosuppressant therapy.
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This paper aims to discuss an exuberant case of PG in a young patient with autoimmune hepatitis (AIH), emphasizing corticosteroid therapy management and the importance of local treatment.
CASE REPORT
We report a 25-year-old female patient with recurrent ulcers on the lower limbs for the past four years. She reported onset with pustules, which progressed to ulceration in the left medial malleolus region. Later, she noticed other similar ulcers on both lower limbs, with disabling local pain. As a relevant medical record, she had type Histopathological study of a lesion revealed unspecific, ulcerated, and chronic inflammation process (Figures 3 and 4) . The search for mycobacteria, fungi, and sporotrichosis serology were negative. PCR for leishmaniasis and leishmanin skin test were also negative. Laboratory tests revealed elevated C-reactive protein, glucose intolerance, and normal liver laboratory tests, except for the elevation of gamma-glutamyltransferase. 
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DISCUSSION
Pyoderma gangrenosum (PG) is a rare dermatosis, and its association with autoimmune hepatitis (AIH) was rarely described in the literature. We report a case with torpid evolution, presenting with multiple and deep ulcers in a young patient with autoimmune hepatitis, causing pain and significant disability. Although the patient was treated with prednisone and azathioprine -both prescribed for AIH -the lesions showed no clinical improvement.
In the present case, PG and the underlying disease did not follow parallel clinical courses, since AIH was inactive. It is known that the course of the PG can be parallel or not parallel in cases associated with underlying IBD. 6 The systemic corticosteroid therapy is the treatment of choice for PG. High initial doses are often necessary, such as prednisone 60-80 mg/daily. 7 In the present case, we initially prescribed prednisone 1 mg/kg/daily, an equivalent to 70 mg/daily. There are reports on the successful use of azathioprine for PG treatment, but they still require further scientific evidence. 8 We believe that the importance given to local treatment was essential for the healing of the lesions. In this particular case, we applied silver sulfadiazine topical 1%, given the large amount of purulent exudate. Although it may be sterile in PG, we suspected secondary infection, considering the recent worsening of the lesion and the increased pain reported by the patient. Then we used carboxymethyl cellulose gel 3%, one of the components of the hydrogel dressing, which has healing properties by aiding cell rehydration and autolytic debridement. 9 Because of the high cost of commercial hydrogel dressing, we chose to use isolated carboxymethyl cellulose.
We further emphasize the slow withdrawal of corticosteroid therapy: after 17 days using 1 mg/kg/daily, given the evolutionary improvement observed, we started to reduce by 10 mg every month; 
